10.17.09 ~ 8.20 ~ Farris ~ Advances in Fillers II

10.17.09 ~ 8.20 ~ Farris ~ Advances in Fillers II - Fall...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: Fall Clinical 2009 Patricia K Farris, M.D. Consultant Medicis Dermik Neutrogena Whats New? 1981 1983 2003 2008 Xyderm I Xyderm II Cosmoderm I, II Evolence Xyplast Cosmoplast Evolence Breeze Pig tendon 35mg/ml type I collagen D-ribose cross-linking Enzymatic digestion of antigen portions Enzymatic digestion of antigen portions No skin testing Multicenter trial, blinded N=149 Split face (NLFs) Evolence vs Restylane Evolence vs Restylane Filled to optimal cosmetic result (OCR) Could receive touch up in 2 weeks Follow up 3 month intervals after OCR up to 12 months Narins et al, Dermatol Surg 2007;33(suppl 2): S213-221 Demonstrated non-inferiority at 6 months ELISA results no antibodies to porcine collagen of clinical significant AEs injection site reactions Further studies published showed persistency of Evolence for 12 months Narins et al, Dermatol Surg 2007;33(suppl 2): S213-221 Narins et al, Dermatol Surg 2008;34:S31-S39...
View Full Document

Page1 / 5

10.17.09 ~ 8.20 ~ Farris ~ Advances in Fillers II - Fall...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online